Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140654 | 1.00 | HCRTR2 (0.39) | HCRTR2DRD2DRD3CYP19A1FAAH | |
| SCHEMBL4140659 | 1.00 | HCRTR2 (0.39) | HCRTR2DRD2DRD3CYP19A1FAAH | |
| SCHEMBL4119739 | 0.88 | ADRA2A (0.37) | HCRTR2FAAH | |
| SCHEMBL4119743 | 0.88 | ADRA2A (0.37) | HCRTR2FAAH | |
| SCHEMBL4119746 | 0.88 | ADRA2A (0.37) | HCRTR2FAAH | |
| SCHEMBL4120052 | 0.82 | ABCB1 (0.45) | HCRTR2DRD2DRD3 | |
| SCHEMBL4120064 | 0.82 | ABCB1 (0.45) | HCRTR2DRD2DRD3 | |
| SCHEMBL4120056 | 0.82 | ABCB1 (0.45) | HCRTR2DRD2DRD3 | |
| SCHEMBL4137837 | 0.82 | HTR2B (0.43) | KMT2AACHE | |
| SCHEMBL4137845 | 0.82 | HTR2B (0.43) | KMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612061-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20090076030-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-20090075982-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-7465733-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2008-12-16 | — | — | US | disclosed |
| EP-1710240-B1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | SERVIER LAB (FR) | 2007-12-05 | — | — | EP | disclosed |
| US-20060229318-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-12 | — | — | US | disclosed |
| EP-1710240-A1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | Les Laboratoires Servier (FR) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075982-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | HCRTR2 15/4885DRD2 81/4885DRD3 85/4885 |
| US-20090076030-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | HCRTR2 15/4885DRD2 81/4885DRD3 85/4885 |
| US-20060229318-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | HCRTR2 15/4885DRD2 81/4885DRD3 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.